Characterization of Immune Responses to RBD-SD1 Nanoparticle Vaccines Derived From ACE2-Capable HKU5-CoV-2, NeoCoV, and HKU5 Merbecoviruses.

Authors

Peter J Halfmann, Jeong Soo Lee, Augustine Duffy, Tong Wang, Bingcheng Huang, James Z Kurdi, Ajay Inampudi, Natasha Chen, Elizabeth Frimpong, Carmen Rai, Yoshihiro Kawaoka, Ravi S Kane

Published in

Biotechnology and bioengineering. Aug 19, 2026. Epub Aug 19, 2026.

Abstract

Recent discoveries of merbecoviruses such as HKU5, NeoCoV, and HKU5-CoV-2 that use angiotensin-converting enzyme 2 (ACE2) as their entry receptor underscore the potential for future spillover to humans. To combat these ACE2-utilizing merbecoviruses, we developed virus-like particle (VLP) vaccines displaying their receptor-binding domain and subdomain 1 (RBD-SD1) antigens fused to SpyTags. These antigens were then conjugated to SpyCatcher-mi3 nanoparticles. Immunization of mice with each RBD-SD1-mi3 vaccine produced robust IgG responses against homologous antigens and measurable but reduced binding to heterologous RBD-SD1 proteins. Antigenic cartography showed that antigenic relationships broadly reflected sequence identity with HKU5 positioned between NeoCoV and HKU5-CoV-2. Despite HKU5 and HKU5-CoV-2 sharing the greatest genetic similarity, cross-reactive titers between these two groups were not substantially higher than those observed with NeoCoV. In a surrogate virus neutralization test (sVNT), sera from mice vaccinated with NeoCoV RBD-SD1-mi3 or HKU5-CoV-2 RBD-SD1-mi3 showed strong inhibition of receptor binding by their respective Fc-fused RBD-SD1 proteins. Sera from mice vaccinated with HKU5 RBD-SD1-mi3 exhibited some cross-inhibition activity against both NeoCoV and HKU5-CoV-2 Fc-fused RBD-SD1. Together, these findings show that the RBD-SD1-displaying nanoparticle vaccine can elicit cross-reactive antibodies against ACE2-binding merbecoviruses and that antigenic relationships are shaped by more than sequence similarity.

PMID:
42617055
Bibliographic data and abstract were imported from PubMed on 20 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.